OR9Q2 Activators
OR9Q2 can influence its activity through various intracellular signaling pathways, primarily involving the elevation of cyclic AMP (cAMP) levels. Forskolin is a direct activator of adenylyl cyclase, leading to an increase in cAMP within cells. This rise in cAMP can activate protein kinase A (PKA), which may phosphorylate OR9Q2, thereby modulating its activity. Similarly, isoproterenol, a beta-adrenergic receptor agonist, increases cAMP levels by stimulating these receptors, which can result in the activation of PKA and subsequent phosphorylation of OR9Q2. IBMX acts by inhibiting phosphodiesterases, enzymes responsible for cAMP degradation, thus indirectly raising cAMP levels and possibly leading to PKA-mediated phosphorylation of OR9Q2.
Other chemical activators work through receptor-mediated pathways to influence OR9Q2 activity. PGE2 binds to its G protein-coupled receptors, causing an increase in cAMP production and PKA activation, which can lead to OR9Q2 phosphorylation. Glucagon, by binding to its specific receptor, also triggers a similar cascade, resulting in PKA activation and potential changes in OR9Q2 activity. The neurotransmitter histamine, via H2 receptors, and the hormone epinephrine, through beta-adrenergic receptors, both stimulate adenylyl cyclase, increasing cAMP and activating PKA, which in turn may phosphorylate OR9Q2. Dopamine acts on D1-like receptors, and adenosine interacts with A2A receptors, both leading to increased cAMP and potential PKA-mediated OR9Q2 activation. Beta2-adrenergic agonists, such as terbutaline and salbutamol, also raise cAMP levels, which can lead to PKA activation and OR9Q2 phosphorylation. Lastly, rolipram, by selectively inhibiting PDE4 and preventing cAMP degradation, can maintain high levels of cAMP within the cell, allowing for sustained PKA activity and possible phosphorylation of OR9Q2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly activates adenylyl cyclase, which increases the production of cyclic AMP (cAMP) within cells. Elevated cAMP levels can lead to the activation of protein kinase A (PKA), which in turn, can phosphorylate and activate various proteins, including OR9Q2 if OR9Q2 is a substrate for PKA or if it is regulated by PKA-dependent pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a synthetic catecholamine that acts as an agonist of beta-adrenergic receptors, leading to increased intracellular levels of cAMP. This elevation of cAMP can activate PKA, which may phosphorylate and activate OR9Q2 if OR9Q2 is part of PKA responsive pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, which degrade cAMP and cyclic GMP (cGMP). By preventing cAMP degradation, IBMX can indirectly increase the activity of cAMP-dependent pathways, potentially resulting in the activation of OR9Q2 through PKA-mediated phosphorylation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G protein-coupled receptors (GPCRs) to activate adenylyl cyclase and subsequent cAMP production. The increase in cAMP can lead to the activation of PKA, which may then activate OR9Q2 through phosphorylation if OR9Q2 is downstream of PKA signaling. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $92.00 $277.00 $969.00 | 7 | |
Histamine can activate H2 receptors, which are GPCRs that stimulate adenylyl cyclase to increase cAMP levels in the cell. This activation of cAMP and subsequent PKA may lead to phosphorylation and activation of OR9Q2 if it is involved in these signaling pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine engages beta-adrenergic receptors, increasing intracellular cAMP levels and activating PKA. PKA can then phosphorylate and potentially activate OR9Q2 if OR9Q2 is part of the signaling cascade influenced by PKA. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can bind to D1-like receptors, which are GPCRs that activate adenylyl cyclase, increasing cAMP levels. This can lead to PKA activation which might phosphorylate and activate OR9Q2 as part of the dopamine signaling pathway. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $33.00 $47.00 $294.00 $561.00 $1020.00 $2550.00 $4590.00 | 1 | |
Adenosine interacts with A2A receptors, which are GPCRs that stimulate adenylyl cyclase, leading to increased cAMP levels. The activation of PKA by cAMP could result in the phosphorylation and activation of OR9Q2 if it is part of the A2A receptor signaling pathway. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $90.00 $371.00 | 2 | |
Terbutaline is a beta2-adrenergic agonist that promotes cAMP production by activating adenylyl cyclase. The resulting PKA activation could phosphorylate and activate OR9Q2 if OR9Q2 is influenced by beta2-adrenergic receptor signaling. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol, another beta2-adrenergic agonist, increases intracellular cAMP, leading to PKA activation. PKA could potentially activate OR9Q2 through phosphorylation if OR9Q2 is a component of the beta2-adrenergic signal transduction pathway. | ||||||